Display options
Cite
Gogiashvili M, Nowacki J, Hergenröder R, et al. HR-MAS NMR Based Quantitative Metabolomics in Breast Cancer. Metabolites. 2019;9(2)doi: 10.3390/metabo9020019.
Gogiashvili, M., Nowacki, J., Hergenröder, R., Hengstler, J. G., Lambert, J., & Edlund, K. (2019). HR-MAS NMR Based Quantitative Metabolomics in Breast Cancer. Metabolites, 9(2), . https://doi.org/10.3390/metabo9020019
Gogiashvili, Mikheil, et al. "HR-MAS NMR Based Quantitative Metabolomics in Breast Cancer." Metabolites vol. 9,2 (2019). doi: https://doi.org/10.3390/metabo9020019
Gogiashvili M, Nowacki J, Hergenröder R, Hengstler JG, Lambert J, Edlund K. HR-MAS NMR Based Quantitative Metabolomics in Breast Cancer. Metabolites. 2019 Jan 22;9(2). doi: 10.3390/metabo9020019. PMID: 30678289; PMCID: PMC6410210.
Copy Download .nbib Format: NLM
Share it on

Metabolites. 2019 Jan 22;9(2). doi: 10.3390/metabo9020019.

HR-MAS NMR Based Quantitative Metabolomics in Breast Cancer.

Metabolites

Mikheil Gogiashvili, Jessica Nowacki, Roland Hergenröder, Jan G Hengstler, Jörg Lambert, Karolina Edlund

Affiliations

  1. Leibniz Institut für Analytische Wissenschaften, ISAS, e.V., 44139 Dortmund, Germany. [email protected].
  2. Leibniz Institut für Analytische Wissenschaften, ISAS, e.V., 44139 Dortmund, Germany. [email protected].
  3. Leibniz Institut für Analytische Wissenschaften, ISAS, e.V., 44139 Dortmund, Germany. [email protected].
  4. Leibniz Research Centre for Working Environment and Human Factors (IfADo), 44139 Dortmund, Germany. [email protected].
  5. Leibniz Institut für Analytische Wissenschaften, ISAS, e.V., 44139 Dortmund, Germany. [email protected].
  6. Leibniz Research Centre for Working Environment and Human Factors (IfADo), 44139 Dortmund, Germany. [email protected].

PMID: 30678289 PMCID: PMC6410210 DOI: 10.3390/metabo9020019

Abstract

High resolution magic-angle spinning (HR-MAS) nuclear magnetic resonance (NMR) spectroscopy is increasingly used for profiling of breast cancer tissue, delivering quantitative information for approximately 40 metabolites. One unique advantage of the method is that it can be used to analyse intact tissue, thereby requiring only minimal sample preparation. Importantly, since the method is non-destructive, it allows further investigations of the same specimen using for instance transcriptomics. Here, we discuss technical aspects critical for a successful analysis - including sample handling, measurement conditions, pulse sequences for one- and two dimensional analysis, and quantification methods - and summarize available studies, with a focus on significant associations of metabolite levels with clinically relevant parameters.

Keywords: HR MAS; NMR; breast cancer; metabolomics

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Magn Reson Med. 1999 Feb;41(2):257-67 - PubMed
  2. MAGMA. 1999 May;8(2):121-8 - PubMed
  3. Anal Biochem. 2000 Jun 15;282(1):16-23 - PubMed
  4. Nature. 2000 Aug 17;406(6797):747-52 - PubMed
  5. J Magn Reson. 2001 Jan;148(1):115-20 - PubMed
  6. NMR Biomed. 2001 Jun;14(4):260-4 - PubMed
  7. J Magn Reson. 2001 Sep;152(1):95-102 - PubMed
  8. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 - PubMed
  9. J Neurosurg. 2002 Jun;96(6):1023-31 - PubMed
  10. NMR Biomed. 2002 Aug;15(5):327-37 - PubMed
  11. Magn Reson Med. 2003 Sep;50(3):515-21 - PubMed
  12. Magn Reson Med. 2003 Sep;50(3):627-32 - PubMed
  13. Org Lett. 2003 Sep 18;5(19):3511-3 - PubMed
  14. NMR Biomed. 1992 Jul-Aug;5(4):179-84 - PubMed
  15. N Engl J Med. 2004 Dec 30;351(27):2817-26 - PubMed
  16. Magn Reson Med. 2005 Aug;54(2):253-7 - PubMed
  17. NMR Biomed. 2006 Feb;19(1):30-40 - PubMed
  18. Magn Reson Med. 2005 Dec;54(6):1547-52 - PubMed
  19. J Am Chem Soc. 2006 Mar 1;128(8):2571-6 - PubMed
  20. Magn Reson Med. 2006 Jun;55(6):1257-64 - PubMed
  21. Breast Cancer Res Treat. 2007 Aug;104(2):181-9 - PubMed
  22. NMR Biomed. 2008 Aug;21(7):677-85 - PubMed
  23. J Chem Phys. 2008 May 14;128(18):184505 - PubMed
  24. NMR Biomed. 2009 Feb;22(2):199-206 - PubMed
  25. NMR Biomed. 2009 Jan;22(1):54-64 - PubMed
  26. J Clin Oncol. 2009 Mar 10;27(8):1160-7 - PubMed
  27. Magn Reson Med. 2009 Mar;61(3):525-32 - PubMed
  28. Biomark Insights. 2007 Apr 18;2:147-54 - PubMed
  29. Phytochem Anal. 2010 Jan-Feb;21(1):22-32 - PubMed
  30. J Proteome Res. 2010 Feb 5;9(2):972-9 - PubMed
  31. NMR Biomed. 2010 May;23(4):424-31 - PubMed
  32. Nat Protoc. 2010 Jun;5(6):1019-32 - PubMed
  33. BMC Cancer. 2010 Aug 17;10:433 - PubMed
  34. Prostate. 2011 Apr;71(5):461-9 - PubMed
  35. BMC Cancer. 2010 Nov 16;10:628 - PubMed
  36. Anal Chem. 1998 Dec 1;70(23):4921-8 - PubMed
  37. Anal Chem. 1999 Jul 1;71(13):2554-7 - PubMed
  38. Clin Cancer Res. 2011 Sep 15;17(18):6012-20 - PubMed
  39. NMR Biomed. 2012 Feb;25(2):369-78 - PubMed
  40. PLoS One. 2011;6(10):e25563 - PubMed
  41. Chem Commun (Camb). 2012 Jan 21;48(6):811-3 - PubMed
  42. Anal Chem. 2012 Jan 17;84(2):994-1002 - PubMed
  43. BMC Cancer. 2012 Jan 25;12:39 - PubMed
  44. NMR Biomed. 2012 Nov;25(11):1271-9 - PubMed
  45. Expert Rev Anticancer Ther. 2012 Aug;12(8):1021-32 - PubMed
  46. PLoS One. 2012;7(12):e51712 - PubMed
  47. PLoS One. 2013 Apr 17;8(4):e61578 - PubMed
  48. Magn Reson Med. 2014 Jun;71(6):1973-81 - PubMed
  49. Sci Rep. 2013 Nov 28;3:3349 - PubMed
  50. PLoS One. 2013 Dec 19;8(12):e83866 - PubMed
  51. Clin Biochem. 2014 Mar;47(4-5):258-66 - PubMed
  52. Breast Cancer Res. 2014 Jan 21;16(1):R5 - PubMed
  53. Lancet. 2014 Jul 12;384(9938):164-72 - PubMed
  54. J Magn Reson. 2014 Jun;243:8-16 - PubMed
  55. Front Chem. 2014 May 30;2:33 - PubMed
  56. Anal Chem. 2014 Nov 4;86(21):10749-54 - PubMed
  57. BMC Cancer. 2014 Dec 12;14:941 - PubMed
  58. Methods Mol Biol. 2015;1277:37-50 - PubMed
  59. J Magn Reson. 2015 Jun;255:34-8 - PubMed
  60. Breast Cancer Res. 2014 May 20;16(3):210 - PubMed
  61. J Magn Reson. 2015 Nov;260:144-60 - PubMed
  62. Front Oncol. 2016 Jan 28;6:17 - PubMed
  63. Nat Rev Drug Discov. 2016 Jul;15(7):473-84 - PubMed
  64. Medicine (Baltimore). 2016 Apr;95(15):e3398 - PubMed
  65. Cancer Metab. 2016 Jun 27;4:12 - PubMed
  66. PLoS One. 2016 Jul 26;11(7):e0159949 - PubMed
  67. PLoS One. 2016 Aug 25;11(8):e0161038 - PubMed
  68. Anal Bioanal Chem. 2017 Feb;409(6):1591-1606 - PubMed
  69. J Proteome Res. 2017 May 5;16(5):1868-1879 - PubMed
  70. Anal Chim Acta. 2017 Aug 8;980:1-24 - PubMed
  71. Ann Oncol. 2017 Aug 1;28(8):1700-1712 - PubMed
  72. NMR Biomed. 2018 Feb;31(2): - PubMed
  73. High Throughput. 2018 Apr 18;7(2):null - PubMed
  74. NPJ Breast Cancer. 2018 May 22;4:11 - PubMed
  75. J Magn Reson B. 1995 Mar;106(3):203-11 - PubMed
  76. Magn Reson Med. 1993 Dec;30(6):672-9 - PubMed
  77. NMR Biomed. 1993 Jan-Feb;6(1):89-94 - PubMed
  78. Magn Reson Med. 1996 Nov;36(5):653-8 - PubMed
  79. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6408-13 - PubMed
  80. Magn Reson Med. 1997 Aug;38(2):179-82 - PubMed
  81. Magn Reson Med. 1997 Sep;38(3):399-403 - PubMed
  82. Magn Reson Med. 1998 Mar;39(3):337-45 - PubMed
  83. Cancer Res. 1998 May 1;58(9):1825-32 - PubMed
  84. Magn Reson Med. 1998 Jul;40(1):166-9 - PubMed
  85. J Magn Reson. 1998 Nov;135(1):194-202 - PubMed

Publication Types